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ABSTRACT 
 
Objective: To establish a rigorous, expert-led, evidence-based approach to the evaluation of licensed 
drugs for repurposing and testing in clinical trials of people with progressive multiple sclerosis (MS). 
Methods: We long-listed licensed drugs with evidence of human safety, blood-brain barrier 
penetrance, and demonstrable efficacy in at least one animal model, or mechanistic target, agreed 
by a panel of experts and people with MS to be relevant to the pathogenesis of progression. We 
systematically reviewed the preclinical and clinical literature for each compound, condensed this 
into a database of summary documents, and short-listed drugs by scoring each one of them. Drugs 
were evaluated for immediate use in a clinical trial and our selection scrutinised by a final 
independent expert review.  
Results: From a short list of 55 treatments, we recommended four treatments for immediate testing 
in progressive MS: R-α-lipoic acid, metformin, the combination treatment of R-α-lipoic acid and 
metformin, and niacin. We also prioritised clemastine, lamotrigine, oxcarbazepine, nimodipine and 
flunarizine.  
Conclusions: We report a standardised approach for the identification of candidate drugs for 
repurposing in the treatment of progressive MS. 
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INTRODUCTION 
 
Multiple sclerosis (MS) is a chronic, primarily inflammatory, disorder of the central nervous system 
(CNS) in which demyelination occurs alongside axonal and neuronal degeneration.[1] There now 
exists an extensive therapeutic armamentarium for the 85% of patients presenting with episodic 
neurological dysfunction (relapsing remitting MS; RRMS).[2] However, the expanding repertoire of 
these anti-inflammatory disease modifying treatments (DMTs) contrasts with a paucity of effective 
therapies for the 15% of people that present with progressive disability (primary progressive MS; 
PPMS), and indeed the 80% of RRMS patients who subsequently develop progression (secondary 
progressive MS; SPMS).[3] While ocrelizumab and siponimod have shown modest benefits in phase 
III trials,[4,5] most immunotherapies have failed in non-active progressive disease. Finding drugs to 
treat progression remains the greatest unmet need for people with MS. 
The reasons for the lack of an effective therapy for progressive MS are multifaceted. The 
pathophysiology of progressive MS is poorly understood (reviewed in [6]), and there is no animal 
model that accurately mimics the entirety of the disease. So, new target and drug discovery are 
challenging. Drug repurposing is attractive, with fewer hurdles before reaching clinical trials, but the 
rationale behind drug selection needs to be carefully considered.[7,8] 
In 2011 the MS Society sponsored an initiative to choose licensed drugs to be trialled in secondary 
progressive MS.[9] Only oral treatments with a putative action against neurodegeneration were 
considered. Highest priority was given to drugs that had been tested in MS, Alzheimer’s disease, 
motor neuron disease / amyotrophic-lateral sclerosis, Parkinson’s disease and/or Huntington’s 
disease. Clinical and laboratory data from each drug were brought, in a standard template, to a 
panel composed of people with MS, and experts in animal models, disease biology, clinical trial 
design and systematic review. The final panel treatment selection was: riluzole, amiloride, 
fluoxetine, ibudilast, oxcarbazepine, pirfenidone and agents of the polyunsaturated fatty acid (PUFA) 
class (including lipoic acid). Of these, both ibudilast and lipoic acid have since shown efficacy in 
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progressive MS in phase 2 trials.[10,11]  The MS-secondary progressive multi-arm randomisation 
trial (MS SMART) study tested riluzole, amiloride and fluoxetine versus placebo in 445 people with 
SPMS.[12] Unfortunately, no treatment effect on brain atrophy (percentage brain volume change) 
was seen over 2 years.[13] 
In 2018, the MS Society set up an expert consortium (Figure 1) to select treatments and design a 
new phase of drug trials in progressive MS utilising a novel adaptive methodology. Working as the 
treatment selection component of this consortium, we augmented the previous strategy with an 
expert and mechanism-led approach, which we describe here.  
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METHODS 
 
Pilot stage of treatment selection 
The original treatment selection group included 10 scientific members [specialist multiple sclerosis 
clinicians, laboratory scientists, people with experience of the pharmaceutical industry] and two 
people with MS. The latter were selected from the MS Society’s Research Network (RN): a group of 
people living with, or caring for, someone with MS, who are trained and experienced in working with 
researchers to strengthen the quality and relevance of research by drawing upon their personal 
experience of MS.  
At the first meeting of the treatment selection group in January 2018 the following principles of 
treatment selection were agreed: the highest priority would be given to safe licensed drugs acting 
on pathological mechanisms thought to be relevant to progression in multiple sclerosis, including 
remyelination; to drugs which cross the blood-brain barrier; and those that had demonstrable 
efficacy in at least one relevant animal model. Experience of the drug’s use in MS or any other 
neurological illnesses was considered but did not weight treatment choice. Immunotherapies, such 
as B-cell depleting drugs, were excluded, given the considerable industrial investment in this area. 
The agreed mechanistic areas were: (i) energy, blood flow and mitochondria; (ii) the neuron and 
axon; (iii) sodium channels; (iv) microglia and astroglia; (v) intrathecal B cells and plasma cells; (vi) 
demyelination and myelin repair; and (vii) antioxidants. It was also agreed that the process of drug 
selection should be iterative, using a modified Delphi method, led by expert opinion within 
treatment selection group, while at each stage independent expert input would be sought. 
We then convened an international treatment selection workshop, held in London in April 2018. 
Leading experts from the research community gave a series of talks in each mechanistic area and 
were asked to suggest drugs for consideration. We also invited representatives of the Cure 
Parkinson’s Trust, the Alzheimer’s Society, Motor Neuron Disease Association, Parkinson’s UK, and 
Medicine Discovery Catapult (MDC), who had undertaken drug repurposing programmes within their 
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own disease area.[14,15] We agreed to draw up a template (a “drug CV”) for each compound based 
on the Cure Parkinson’s Trust linked clinical trials initiative dossier model. These documents included 
information on pharmacodynamics, pharmacokinetics, mechanism of action, and evidence-base in 
vitro, in vivo, and in clinical trials (Table 1). This CV condensed and systematised the literature on 
each drug into an accessible summary manuscript; a drug CV for each potential treatment would be 
completed by at least 2 members of the treatment selection group.  
 
Table 1: Information recorded in the drug CV 
Summary information 
 Drug name 
 Regulatory status 
 Mechanistic target 
 Dose for human use (and appropriateness for MS) 
 Key safety concerns 
 Intellectual property 
 Outstanding critical issues 
 Overall evaluation  
Absorption, distribution, metabolism, excretion, pharmacokinetics and pharmacodynamics 
 Chemical structure 
 Molecular target 
 Pathway affected 
 Human pharmacodynamics 
 Human pharmacokinetics 
 Blood-brain barrier penetrance 
 Route of administration 
 - 9 - 
 Licenced indication 
 Dose for licenced indication 
 Dose suitability for MS 
 Known, or anticipated, drug-drug interactions 
Scientific rationale 
 Efficacy in in vitro models 
 Efficacy in in vivo models 
 Efficacy for primary indication 
 Efficacy in people with MS (if applicable) 
 Particular subgroups of people with MS likely to benefit (if applicable) 
Safety 
 Animal safety issues 
 Therapeutic ratio (if known) 
 Safety record in humans 
 Safety record in people with MS 
 Monitoring requirements 
 Any particular drug-drug interaction that would limit use in MS 
Landscape review 
 Is there active pre-clinical research on the use of this drug in MS? Where? 
 Has the Progressive MS Alliance prioritized this drug? 
 Are there any relevant trials listed on clinical trials databases? 
 
There was then a call for suggestions for repurposed drugs to members of the committee, clinicians, 
experts from the wider MS research community, people with MS, and the public, via a web-based 
system that was advertised to the MS Society’s mailing lists. Contributors were prompted to 
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describe the scientific rationale for their proposed intervention. After four months, the call was 
closed, a long list of drugs was compiled, and drug CVs completed for each. 
The scientific members of the committee scored each drug CV according to an agreed system 
prioritising safety and efficacy (Table 2a). Members of the MS Society’s research network also scored 
each drug, for ease of administration, tolerability, safety and monitoring requirements based on the 
drug CV and the European Medicines Agency’s (EMA) patient information leaflets (Table 2b). The 
scores were collated before a second face-to-face meeting.  
 
Table 2: scoring system for shortlisting drug CVs 
a) For scientific members of the panel 
Safety – Are the safety data for the treatment satisfactory? To include any regulatory warnings, 
adverse events, drug-drug interactions, therapeutic index, and safety profile. (Score 0-2) 
Efficacy – Do we have sufficient evidence that the treatment is likely to be effective in slowing 
progression? To include in vitro and in vivo experimental models, blood-brain barrier penetration, 
along with human data where available. (Score 0-2) 
Overall evaluation - Priority level for the treatment (select one) 
a. Licensed drug, ready for a phase 2 trial in MS, high priority 
b. Licensed drug, ready for a phase 2 trial in MS, low priority 
c. Licensed drug, with critical issues to be resolved before a phase 2 trial in MS 
d. Interesting drug, with considerable pre-clinical work to be done 
e. Poor scientific rationale: not to be prioritised 
b) For research network members (people with MS) 
Administration – is the method of taking the drug acceptable? To consider whether it is a tablet, 
injection or infusion as well as how often it needs to be taken. (Score 0-2) 
Side effects and risks – is the safety of the drug acceptable? To consider both the immediate side 
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effects and risks as well as the long term. (Score 0-2) 
Overall evaluation - Priority level (select one) 
a. I would take this drug even if it only moderately slowed the progression of my MS. 
b. I would take this drug if it stopped the progression of my MS. 
c. I would not take this drug even if it stopped the progression of my MS. 
 
At this meeting, in September 2018, the treatment selection group (voting) members were joined by 
new members of the research community and research network (invited attendees), to provide a 
fresh perspective on the drug list. Each drug was presented, discussed and given an overall score 
(between 0 lowest and 5 highest). The results were further reviewed and discussed, before all 
attendees ranked their top 5 drugs, which resulted in a list of seven prioritised drugs. 
In parallel to the pilot stage of treatment selection, the MS Society commissioned Medicines 
Discovery Catapult (MDC) to independently identify licensed drugs that might impact progressive 
MS. This was undertaken to scrutinise our long list of drugs which had been compiled through the 
aforementioned mechanism of drug proposals. MDC searched for all ongoing, or completed, trials in 
people with MS to identify drugs being tested for any type of MS. They then characterised their 
molecular targets and sought other compounds that were predicted to impact these targets. The 
final list was pruned of immunotherapies and symptomatic drugs, as well as those that did not cross 
the blood-brain barrier, and any not on the original long list were added for consideration during the 
final stage of treatment selection. 
 
Final stage of treatment selection 
The treatment selection group appointed new members, and some original members left, leaving 13 
scientific and 6 research network members. A renewed call for drug proposals was opened, and the 
newly formed group reviewed any new suggested compounds, the original long list of drugs 
considered during the pilot stage, and those generated by Medicines Discovery Catapult, resulting in 
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a new long list of 29 drugs. Each of these had a drug CV compiled or updated by a team of four, two 
with a scientific background and two clinicians. The 13 scientific members of the treatment selection 
group then scored each drug CV according to a simplified scoring system based on safety, efficacy 
and an overall assessment of priority (Table 2). Similarly, 6 research network (RN) members of the 
treatment selection group and an additional 10 invited RN members scored between 5 and 10 of the 
drug CVs, with additional access to the EMA-approved patient information leaflet, such that at least 
5 scores were recorded for each drug. The highest ranked 12 drugs from the collated scores formed 
the shortlist for a third face-to-face meeting in September 2019 of the treatment selection group, 
with a new group of invited experts and people with MS. Members of the treatment selection group 
had the option to rescue a low scoring drug in advance of the meeting by presenting a case for its 
inclusion and it being accepted by majority vote. For the meeting, each drug was presented by one 
scientific and one research network member, who focussed on the scientific case and attractiveness 
to people with MS, respectively. Drugs were then scored out of 5 and the resulting ranking discussed 
before each attendee individually ranked up to 5 drugs ready for use in a clinical trial.  
The drug CVs of the treatments recommended by this meeting, and the two highest scoring drugs in 
the sodium channel antagonist class, were sent to 4 independent international MS experts outside 
the UK to achieve a further layer of scrutiny of the decisions and to elicit any information on the 
drugs that was not publicly available. Their comments were collated and considered alongside the 
outcome of the final treatment selection meeting by the Treatment Advisory Committee (Figure 1). 
This committee advised on the final drug selection for the MS Society’s Efficient Clinical Trials 
Platform, which is intended to evaluate repurposed treatments quickly and affordably. This 
committee comprised 6 scientific members and 3 people affected by MS. They assessed the 
prioritised list on the basis of scientific evidence, but also in the context of other trials known to be 
going ahead elsewhere. They also scrutinised drug mechanisms and whether the chosen trial design 
and outcome measures would allow detection of treatment effects.  This facilitated a final decision 
to be made for the drugs to be tested in a platform trial (Figure 1). 
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RESULTS 
 
Pilot stage of treatment selection 
44 treatments were proposed during the 2018 call for drug suggestions, with at least one believed to 
act on each of the target mechanisms. 35 were deemed by the treatment selection group to have 
sufficient scientific rationale for consideration, and drug CVs were completed by its scientific 
members. Each was then scored, prioritising considerations of efficacy and safety as detailed in 
Table 2, leading to a shortlist of 19 compounds to be discussed face-to-face in September 2018. At 
that meeting, each drug was presented and discussed before being scored again, collated separately 
for the members of the treatment selection group (voting members) and the invited attendees 
(experts and people affected by MS) (Figure 2).  After open discussion of these scores, the treatment 
selection group members ranked their preferred 7 drugs. 
During this pilot stage we learned that the drug CVs were effective, but needed more consistency in 
authorship to promote comparable levels of detail in each CV, and multiple contributors from 
different backgrounds to encourage impartiality in the presentation of the literature for each 
compound. We also reflected on the valuable contributions from people affected by MS, who were 
in a unique position to weigh the safety and tolerability of each drug and consider the level of 
benefit they would require to take the proposed treatment for their MS. The group resolved that 
more research network members should be invited onto the treatment selection group to maximise 
representation of different viewpoints from within the MS community and to share the burden of 
scoring CVs and presenting drugs at meetings beyond the 2 original members. 
 
Final stage of treatment selection 
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MDC identified 320 licensed drugs which had a mechanism similar to a drug that had been tried in 
multiple sclerosis.[16] Once immunotherapies, drugs which did not cross the blood brain barrier and 
duplicates were removed, guanabenz and trazodone remained from this list. These were added to 
the 44 treatments that emerged from the pilot phase. During the renewed call for proposals in 2019, 
new members of the treatment selection committee and outside experts contributed these new 
suggestions: domperidone, benztropine, prednisolone, ibudilast, spironolactone, oxcarbazepine, 
hydroxychloroquine, niacin and the combination of metformin and R- -lipoic acid. This long list of 55 
treatments was screened by the new treatment selection group, and 28 drugs and one combination 
therapy were chosen to have comprehensive drug CVs completed.  
12 scientific members of the group scored all 29 drug CVs and 16 research network (RN) members (6 
of which were members of the treatment selection group) scored up to 10 of the drug CVs, with 
additional access to the EMA-approved patient information leaflet, such that 5 research network 
scores were recorded for each drug. The scientific scores were ranked and 13 drugs and 1 
combination treatment (metformin and R- -lipoic acid) were short-listed. If a scientific member 
disagreed with a drug excluded at this stage, they were able to make a case for its inclusion to the 
group and add to the shortlist by majority vote. Flunarizine and lamotrigine, which had initially been 
excluded from the list of 12 at the CV scoring stage, were re-added to the list in this way. 
The 14 shortlisted treatments were discussed and scored, one by one, at a face-to-face meeting of 
the treatment selection group and invited attendees. The collated scores (Figure 3) were then 
discussed and debated before the treatment selection group ranked up to 5 drugs, which were 
ready for immediate use in a phase 2 clinical trial.  The final shortlist list of drugs were, in order of 
preference: R-α-lipoic acid, metformin, the combination treatment of R-α-lipoic acid and metformin, 
and clemastine. We considered that niacin, flunarizine, and nimodipine were particularly promising, 
but the treatment selection group felt they needed more pre-clinical work. 
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This selection, in addition to the 2 highest scoring sodium channel antagonist drugs (lamotrigine and 
oxcarbazepine), were sent to 4 independent expert reviewers. They scored each compound on 
safety and efficacy and ranked the drugs by priority level. They were also asked to provide 
information on any of these drugs that was not publicly accessible. The results of this procedure 
were considered by the Treatment Advisory Committee of the MS Society’s Efficient Clinical Trials 
Platform (Figure 1), and a final order of prioritisation was made (Table 3). The top 4 were 
recommended as the most promising for clinical evaluation. The pathway of each drug through 
these procedures is summarised in Figure 4. 
 
 
Final list of drugs for 
prioritisation 
Mechanism of action 
1. R-α-lipoic acida  Dietary supplement, approved in Germany for diabetic 
neuropathy; anti-oxidant, anti-inflammatory, and 
neuroprotective[11,34,35] 
2. Metforminb Anti-hyperglycaemic agent used for type 2 diabetes mellitus; 
anti-inflammatory[23] and promotes remyelination[25] and 
neuroprotection[24]  
3. R-α-lipoic acid and 
metformin 
combination 
Mechanisms as above; complimentary mechanistic targets and 
neuroprotective in combination[27] 
4. Niacinc Anti-hypercholesterolaemic drug; promotes oligodendrocyte 
proliferation,[29] remyelination,[30] and neuroprotection[28] 
5. Clemastine Antihistamine used for allergic rhinitis; off-target anti-muscarinic 
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(M1) action which promotes oligodendrocyte progenitor 
differentiation and remyelination[32,33] 
6. Lamotrigine Sodium channel antagonist widely used as an anticonvulsant; 
neuroprotective effects[36] 
7. Oxcarbazepine Sodium channel antagonist widely used as an anticonvulsant;; 
neuroprotective effects[37] 
8. Nimodipine Calcium channel antagonist used to treat vasospasm in 
subarachnoid haemorrhage; promotes remyelination, 
neuroprotection,[38] and restores CNS perfusion and 
oxygenation[39] 
9. Flunarizine Migraine prophylactic; neuroprotective effects[40] 
 
Table 3. Final recommendations of repurposed interventions for clinical testing in progressive MS. 
The top 4 were determined to be the most promising for clinical evaluation. a1200 mg/day, b1 
gram twice daily, starting at 500mg twice daily, c750mg twice daily of slow release formulation of 
Niaspan. 
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DISCUSSION 
 
The pathogenesis of progressive MS is complex, multifaceted and poorly understood. As with many 
other neurodegenerative diseases, there are no licensed treatments. This remains the greatest 
unmet need for the more than 2.3 million people affected by MS globally.[17] Placed in context of 
the high cost, long time, and high attrition rate from target selection to regulatory approval via 
conventional pathways, there are compelling reasons to explore opportunities provided by drug 
repurposing. This nevertheless presents a substantial challenge. The myriad reasons for the prior 
failure to find an effective treatment remain,[6] and the optimum process for selection of drugs to 
progress to repurposing clinical trials are not standardised. Procedures for synthesising experimental 
and clinical trial data to enable rational drug selection are required to maximise the chance of 
successful clinical development. 
The UK MS Society Clinical Trials Network was initiated in 2007 and commissioned key underpinning 
work including a review of animal and human data on promising drugs. Given the mechanistic 
overlap between SPMS and other neurodegenerative disorders (namely Alzheimer’s disease, 
Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis), their strategy centred 
on a systematic review and meta-analysis of clinical and preclinical data for agents previously tested 
in these illnesses.[9] The ensuing list prioritised ibudilast, riluzole, amiloride, fluoxetine, pirfenidone, 
oxcarbazepine and agents of the polyunsaturated fatty-acid (PUFA) class. Ibudilast and lipoic acid 
proved successful at phase 2,[10,11] but unfortunately riluzole, amiloride and fluoxetine did not 
reduce brain atrophy in the MS-SMART study compared to placebo.[12,13]  
Here we describe a rigorous, expert-led, evidence-based approach to the selection of licensed 
compounds for repurposing in clinical trials of people with progressive forms of MS, led by scientific 
and clinical experts as well as people with MS, involving repeated rounds of assessment, scoring, and 
independent peer review. We identified key biological mechanisms, performed an exhaustive 
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literature search on identified drugs, and went through two cycles of shortlisting and prioritisation. 
We selected this strategy to retain the evidence-based approach of previous mechanisms of drug 
selection, but with added emphasis on expert opinion and independent expert review which, in our 
view, would enable our selection to be based on current scientific opinion and more readily identify 
barriers and knowledge gaps that might affect trials of the proposed compounds. A particular 
contrast between our strategy and that previously used was that we did not prioritise agents that 
had previously been subject of clinical trials of people with neurodegenerative illnesses and we 
required all candidates to have evidence of blood-brain barrier permeability. Other differences are 
summarised in Table 4.  
It is noteworthy that our first ranked drug, lipoic acid, was also prioritised in the 2011 drug selection 
initiative, despite the contrasting methodologies. Three interventions – R-α-lipoic acid (R-ALA), 
metformin and niacin – and one combination preparation – of metformin and R-α-lipoic acid – were 
identified as being priorities for clinical evaluation in cohorts of people with progressive MS, and as 
having sufficient data to permit immediate entry into a phase 2 trial. Clemastine, lamotrigine, 
oxcarbazepine, nimodipine and flunarizine were also felt to be promising and ranked in order of 
priority. 
R-α-lipoic acid is the R-enantiomer that makes up 50% of the racemic mixture (R and S) of lipoic acid, 
a dietary supplement approved in Germany for the treatment of diabetic neuropathies. It has 
previously been shown to be a potent antioxidant, have anti-inflammatory properties,[18,19] and 
reduce excitotoxic damage;[20] while the R enantiomer has superior pharmacokinetic, antioxidant 
and neuroprotective properties than the S enantiomer.[21] When given to 51 people with SPMS, it 
was shown to have a small benefit to brain atrophy.[22]  
Metformin, a biguanide licensed for human use in type 2 diabetes, has previously been 
demonstrated to reduce inflammation in progressive and relapsing experimental autoimmune 
encephalomyelitis models,[23] is neuroprotective in models of glucose 
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deprivation/reoxygenation[24] and, more recently, has been shown to reverse an age-associated 
barrier to the ability of oligodendrocyte progenitor cells to respond to differentiation factors and 
facilitate subsequent remyelination.[25] Additionally, it has previously been used in 20 people with 
MS, and demonstrated a reduction in the number of new or enlarging T2 lesions compared to 
placebo.[26] The complimentary mechanistic targets of metformin and R-ALA, as well as the 
potential for synergy,[27] led to the combination of the two featuring on our prioritised list. 
Niacin, a nicotinamide adenine dinucleotide (NAD) precursor in use for the treatment of 
hypercholesterolaemia, has previously been shown to be protective against activated microglial-
induced neurotoxicity[28] and to promote oligodendrocyte proliferation in vitro.[29] In line with 
these observations, it reduces axonal degeneration, delays progression, and increases 
oligodendrocyte proliferation in extrinsic allergic encephalomyelitis.[28,29] While ranked below 
clemastine by the treatment selection group, data that was unpublished at the time came to light 
during the treatment advisory committee review: niacin also enhances myelin phagocytosis by 
microglia, leading to increases in oligodendrocyte progenitor cell numbers and improved 
remyelination in mice.[30] Niacin has not yet been trialled in people with multiple sclerosis. 
Finally, clemastine is a first generation anti-histamine that was identified in two separate screens as 
being able to stimulate oligodendrocyte progenitor cells to differentiate and carry out the first 
stages of remyelination.[31,32] This subsequently demonstrated a small, but statistically significant, 
improvement in the latency of the full-field visual evoked potential of people with relapsing MS and 
chronic stable optic neuropathy; interpreted as a remyelinating effect in the optical pathway.[33]  
A particular strength of our methodology is the multiple layers of revision and review. By 
undertaking a pilot of treatment selection, we refined the procedures by which we evaluated the 
literature and assessed each compound to facilitate robust comparisons of agents with disparate 
mechanistic targets and safety profiles. We also ratified our procedures for drug identification by the 
work of Medicines Discovery Catapult, which generated a list of drugs of which only 2 had not 
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previously been identified. Finally, by sending our list of prioritised treatments for external peer 
review we have better ensured scrutiny of both our methods and our selection.  
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Table 4. Comparison between the current methodology and that previously used in 2011;[9] MS, 
multiple sclerosis; AD, Alzheimer’s disease; ALS, amyotrophic-lateral sclerosis; PD, Parkinson’s 
disease; HD, Huntington’s disease; BBB, blood-brain barrier. 
 2011 2019 
Method of drug 
identification 
Thorough and systematic search of 
online databases (PubMed, ISI Web 
of Knowledge, Embase, 
Clinicaltrials.gov, Cochrane MS 
group)  
Calls for recommendations from 
academics, clinicians, and people 
with MS. 
Systematic search of online 
databases by medicines discovery 
catapult 
Previous clinical trial 
use 
Previously used in a 
neurodegenerative disease 
including progressive MS, PD, HD, 
AD, and ALS. 
Human safety data required only 
Mechanistic targets Excluded immunosuppressant 
mechanism of action. 
Combination treatments excluded. 
Priority given to candidates 
targeting several mechanistic 
targets. 
Excluded those with solely 
immunosuppressant mechanism. 
Combination treatments accepted 
Method of 
administration 
Oral Any method of administration 
CNS penetration Reviewed at selection meeting Evidence of BBB permeability 
required at study entry 
Safety Excluded those with significant Excluded those with significant 
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adverse effects associated with 
treatment. 
adverse effects associated with 
treatment. 
Method of selection Systematic evaluation of 
publications pertaining to each 
candidate. 
Systematic review of experimental 
autoimmune encephalomyelitis 
(EAE) preclinical data for each 
candidate. 
Scrutiny of each drug by an 
international multi-disciplinary 
committee 
Systematic evaluation of preclinical 
and clinical publications pertaining 
to each candidate. 
Formation of a database of drug 
CVs. 
Rating of these by scientific panel. 
Presentation and decision at 
international multi-disciplinary 
meeting 
Input from people 
affected by MS 
Patient representatives acting as 
external advisors 
6 members of MS research network 
on voting panel. 
Scoring of drug CVs by at least 5 
people with, or affected by, MS. 
Members of MS research network 
at treatment selection meeting. 
Peer review External advisors with a range of 
expertise including animal models, 
disease biology, clinical trial design, 
systematic review and patient 
representation. 
Methodology and final treatment 
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FIGURE LEGENDS 
 
Figure 1.  Above Summary of the UK MS Society’s expert consortium for progressive MS clinical 
trials, which has been set up to test treatments in an adaptive platform trial, termed the efficient 
clinical trials platform. The treatment selection group and treatment advisory committee were 
responsible for formulating the prioritised list of drugs to enter the clinical trial. Below Flow chart 
of the procedures undertaken during the final round of treatment selection by the treatment 
selection element. *Drug CVs were completed by 4 members of the treatment selection group – 2 
with a scientific background and 2 MS specialist clinicians. **Drugs failing to reach the short list of 
drugs on account of a low score, could be added back for consideration at the panel meeting if 
reasons were proposed by a member of the treatment selection group and its rescue approved by 
majority vote. MDC: medicines discovery catapult; PPI: patient and public involvement. 
 
Figure 2. Outcome of the pilot screen of candidate interventions. Mean scores (out of 5) of each 
drug by voting members of the treatment selection group and invited attendees are displayed in 
descending order. Inset: the provisional list for prioritisation agreed by the voting members of the 
committee. 
 
Figure 3. Outcome of the final meeting of the treatment selection group during the final stage of 
candidate screening. The mean scores (out of 5) for the 14 shortlisted compounds presented at 
the meeting are divided into those awarded by voting members of the panel and invited 
attendees. 
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Figure 4. Summary of the pathway of each drug through the treatment selection process to yield a 
final prioritised list of drugs. 
 
 
